National Hospital Organization Shikoku Cancer Center

Site:	National Hospital Organization Shikoku Cancer Center
Address:
City:	Matsuyama
State:
Zip:	791-0280
Country:	Japan

Phase	Trial	Trial Status	Site Status [asc]	Drug	NCT#
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712